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Infection-related cancers: prioritising an important and 
eliminable contributor to the global cancer burden
In the past two decades, several studies1,2 have 
consistently found that up to one-sixth of cancers 
worldwide are attributable to infectious pathogens. 
Cancers caused by infectious agents present unique 
opportunities for prevention and treatment; therefore, 
a detailed understanding of how infections contribute 
to cancer incidence, as well as the geographical and 
demographic diversity and natural history (ie, response 
to treatment and mortality) of infection-related cancers, 
is crucial.
In The Lancet Global Health, Martyn Plummer and 
colleagues3 update an analysis of the global burden of 
infection-related cancers using data from GLOBOCAN 
2012. As an enhancement to their previous publications, 
the authors now include country-level analyses of the 
total burden of infection-related cancers. As Plummer 
and colleagues acknowledge, the proportion of cancers 
caused by infectious agents is likely to be under-
represented in this analysis. Besides the methodological 
reasons discussed in the Article, two additional factors 
might also contribute to a higher burden of infection-
attributable cancers than recognised at present. First, 
the authors only counted cancers associated with 
viral infections as “HIV-associated”. A wide variety 
of cancers, including many that are not presently 
associated with pathogens (eg, lung, skin, and kidney 
cancers, and leukaemia), are now known to have 
increased prevalence in HIV-infected individuals.4 HIV 
is considered a group 1 carcinogen by the International 
Agency for Research on Cancer,5 and a direct role of 
HIV in the genesis of many cancers is also supported by 
ﬁ ndings from several prospective cohort studies and 
translational research.6,7 Attribution of more cancers 
to HIV infection among the more than 36 million HIV-
infected individuals worldwide would increase the 
proportion of infection-attributable cancers, especially 
in HIV-endemic regions. 
Second, as supported by the discovery of two new 
human tumour viruses in the past two decades, human 
herpesvirus type 8 and Merkel cell polyomavirus, 
there are likely to be additional cancer types that are 
attributable to novel infectious agents. Lung and 
lip cancer, as well as squamous cell carcinoma of the 
conjunctiva, have all been reported to have increased 
incidence in individuals with immunosuppression8 
and are likely to be caused by infectious agents. 
Similarly, new pathogens might be identiﬁ ed in the 
cancers that are only partly attributable to infections 
at present, such as the substantial fraction of 
human-papillomavirus-negative penile, vulvar, and 
oropharyngeal cancers. 
Although the more than 2 million cases of infection-
associated cancer diagnosed annually is substantial, 
it is notable that nearly two-thirds of such cases 
occur in less developed regions. It is reasonable 
to speculate, as the authors do, that economic 
disparities account for the imbalanced prevalence of 
infection-associated cancers worldwide. However, it 
is important to consider other potential contributors 
because they might inform the biology of infection-
related cancers or point to additional prevention 
strategies. Immunogenetic factors aﬀ ect both the 
acquisition of infection-causing pathogens and the 
rate of progression from primary infection to cancer.9 
Co-infection with other pathogens that are endemic 
to low-resource regions—eg, HIV, Mycobacterium 
tuberculosis, malaria parasites, and other parasites—
might also increase the risk of developing infection-
associated cancers. Finally, complex interactions 
might exist between behavioural, environmental, 
and infectious factors that predispose individuals 
to infection-related cancers to a greater extent in 
sub-Saharan Africa than in other regions. Therefore, 
elucidating the reasons for the geographical disparities 
in infection-related cancers is crucial to reducing the 
burden of these malignancies in settings with limited 
resources.
Unique opportunities for prevention and treatment 
of infection-related cancers exist. Vaccination 
against hepatitis B virus and human papillomavirus, 
as well as screen-and-treat approaches for human 
papillomavirus, has already begun to decrease the 
incidence of cancers attributed to these infectious 
agents. With novel eﬀ ective treatment regimens for 
hepatitis C, similar trends can be expected in the future 
if access is expanded worldwide. However, the four 
Published Online
July 25, 2016
http://dx.doi.org/10.1016/
S2214-109X(16)30169-3
See Articles page e609
Comment
e581 www.thelancet.com/lancetgh   Vol 4   September 2016
pathogens associated with the highest number of 
cancers—hepatitis C virus, Helicobacter pylori, Epstein-
Barr virus, and human herpesvirus type 8—have no 
existing vaccines. Furthermore, a vaccine against HIV 
has enormous public health ramiﬁ cations, not least of 
which is a reduction in cancer incidence. Thus, increased 
eﬀ orts and focus on vaccine development are of 
paramount importance. Other strategies to reduce the 
incidence of infection-related cancers are also worthy of 
consideration—eg, chemoprevention (ie, early initiation 
of antiretroviral therapy in HIV-infected individuals, 
eradication of H pylori, or prophylactic antiviral therapy 
in high-risk individuals) and behavioural or public health 
interventions to reduce incident cancer-associated 
infections. Finally, targeting the infectious cause of 
cancer might give rise to eﬀ ective and inexpensive 
treatment strategies with minimal toxicity, such as the 
treatment of mucosal-associated lymphatic tumours 
with antibiotics.10
With the availability of vaccines, screen-and-treat 
approaches, and eﬀ ective drugs to treat hepatitis C virus, 
H pylori, and HIV infections, the question is no longer 
limited to what to do but now extends to how to 
implement. The expanding focus from basic research, 
drug development, and clinical trials that are historically 
concentrated in high-income countries, to basic, 
translational, and implementation science done in 
collaboration with centres in endemic areas, has the 
potential to both reduce the burden of infection-related 
cancers and shed light on presently unknown pathways 
in carcinogenesis.
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